摘要
目的:评价多西他赛联合FOLFOX4方案一线治疗晚期胃癌的疗效及毒副反应。方法:32例Ⅲ-Ⅳ期胃癌患者,应用多西他赛50mg/m^2·d1,奥沙利铂85mg/m^2·d1,亚叶酸钙200mg/m^2 IV d1、2,5-FU 400m^2 IV d1、2,5-FU 600mg/m^2 CIV 22h d1、每2周重复。结果:近期有效率(CR+PR)56.2%(19/32),中位TIP时间6.5月,1年存率43.5%,生活质量改善62.5%。主要不良反应为骨髓抑制66.9%及外周神经毒性,发生事分别为66.9%、52.5%,多为Ⅰ-Ⅱ度。结论:多西他赛联合FOLFOX4治疗晚期胃癌疗效好,不良反应可耐受。
Objective：To evaluate the efficacy and side-effect of Docetaxel plus FOLFOX4 as first-line chemotherapy in patients with advanced gastric cancer.Methods：32 patients received intravenous Docetaxel 50mg/m^2（day1） with FOLFOX4（oxaliplatin 85mg/m^2 dl,CF 200mg/m^2 IV d1, 2,5-FU 400mg/m^2 IV d1, 2, 5-FU 600mg/m^2 CIV 22h d1, 2）,which are repeated every 2 weeks. Results：32 patients were evaluated for responds. The overall clinical response rate was 56.2% （19/32）. The time to progression was 6.5 months. Median One year survival rate was 43.5%, and 75% cases acquired improved life quality. The major toxicity included degree bone marrow inhibition（66.9）,neuro logical toxicity（52.5%）.The most are I - II degree toxicity. Conclusion：The combination of Docetaxel and FOLFOX4 is an effective therapy for the patients with advanced gastric cancer, which toxicity was acceptable.
出处
《中国医药导刊》
2009年第9期1521-1522,共2页
Chinese Journal of Medicinal Guide
